Prognostic Value of CT-based Skeletal Muscle and Adipose Tissue Mass and Quality Parameters in Patients with Liver Metastases and Intrahepatic Cholangiocarcinoma Undergoing Yttrium-90 Radioembolization

Overview

Journal Eur Radiol

Date 2025 Jan 21

PMID 39838088

Authors

Yan Zhao

Fabio Becce

Romain Balmer

Ricardo H do Amaral

Yasser Aleman-Gomez

Emilie Uldry

Montserrat Fraga

Georgia Tsoumakidou

Nicolas Villard

Alban Denys

Antonia Digklia

Niklaus Schaefer

Rafael Duran

Affiliations

Soon will be listed here.

Abstract

Objectives: To investigate baseline patient characteristics associated with the risk of computed tomography (CT)-based sarcopenia and assess whether sarcopenia and other morphometric parameters influence survival outcomes in patients with liver metastases and cholangiocarcinoma after Yttrium-90 radioembolization.

Materials And Methods: We retrospectively analyzed 120 cancer patients (mean age, 62 ± 13.3 years, 61 men) who underwent preprocedural CT. Skeletal muscle index (SMI) was measured at the L3 vertebral level to identify sarcopenia. The Cox proportional hazard model was performed to assess the prognostic value of the variables, and Kaplan-Meier analysis with log-rank text was used for overall survival (OS) assessment.

Results: Sarcopenia was diagnosed in 70 patients (58.3%). The multivariate regression analysis demonstrated that male sex, body mass index (BMI), visceral fat radiation attenuation (VFRA), skeletal muscle radiation attenuation (SMRA), and subcutaneous fat radiation attenuation (SFRA) were associated with the incidence of sarcopenia with the odds ratio of 8.81 (95% CI, 2.09-37.1, p = 0.003), 0.64 (95% CI, 0.48-0.85, p = 0.002), 1.23 (95% CI, 1.06-1.42, p = 0.006), 0.79 (95% CI, 0.69-0.91, p = 0.001) and 0.84 (95% CI, 0.76-0.93, p = 0.001), respectively. Age, skeletal muscle index, and tumor subtypes were independent prognostic factors for OS with the hazard ratio of 1.03 (95% CI, 1.01-1.05, p = 0.01), 0.92 (95% CI, 0.86-0.99, p = 0.021) and 2.09 (95% CI, 1.31-3.33 p = 0.002), respectively. In patients with intrahepatic cholangiocarcinoma, median OS was significantly longer in the non-sarcopenic group than in the sarcopenic patient (25.9 versus 6.5 months, p = 0.029).

Conclusion: Male sex, BMI, VFRA, SMRA, and SFRA were associated with the incidence of sarcopenia. SMI value could be used as a biomarker for OS in patients treated with Yttrium-90 radioembolization.

Key Points: Question The prognostic significance of CT-based sarcopenia and other morphometric parameters in patients with liver metastases and cholangiocarcinoma undergoing Yttrium-90 radioembolization remains unclear. Findings A high skeletal muscle index has been identified as an independent protective factor for overall survival in cancer patients treated with Yttrium-90 radioembolization. Clinical relevance The negative impact of CT-based sarcopenia has been confirmed in the context of Yttrium-90 radioembolization. Clinicians should strive to prevent the progression of sarcopenia or maintain skeletal muscle index in perioperative management.

References

Chen L, Liu L, Woo J, Assantachai P, Auyeung T, Bahyah K . Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014; 15(2):95-101. DOI: 10.1016/j.jamda.2013.11.025. View

Hasenauer A, Forster C, Hungerbuhler J, Perentes J, Abdelnour-Berchtold E, Koerfer J . CT-Derived Sarcopenia and Outcomes after Thoracoscopic Pulmonary Resection for Non-Small Cell Lung Cancer. Cancers (Basel). 2023; 15(3). PMC: 9913444. DOI: 10.3390/cancers15030790. View

Cruz-Jentoft A, Sayer A . Sarcopenia. Lancet. 2019; 393(10191):2636-2646. DOI: 10.1016/S0140-6736(19)31138-9. View

Ebadi M, Moctezuma-Velazquez C, Meza-Junco J, Baracos V, DunichandHoedl A, Ghosh S . Visceral Adipose Tissue Radiodensity Is Linked to Prognosis in Hepatocellular Carcinoma Patients Treated with Selective Internal Radiation Therapy. Cancers (Basel). 2020; 12(2). PMC: 7072301. DOI: 10.3390/cancers12020356. View

Morley J, Anker S, von Haehling S . Prevalence, incidence, and clinical impact of sarcopenia: facts, numbers, and epidemiology-update 2014. J Cachexia Sarcopenia Muscle. 2014; 5(4):253-9. PMC: 4248415. DOI: 10.1007/s13539-014-0161-y. View

Rolland Y, Czerwinski S, Abellan van Kan G, Morley J, Cesari M, Onder G . Sarcopenia: its assessment, etiology, pathogenesis, consequences and future perspectives. J Nutr Health Aging. 2008; 12(7):433-50. PMC: 3988678. DOI: 10.1007/BF02982704. View

Tijerina A . The biochemical basis of metabolism in cancer cachexia. Dimens Crit Care Nurs. 2004; 23(6):237-43. DOI: 10.1097/00003465-200411000-00001. View

Cruz-Jentoft A, Bahat G, Bauer J, Boirie Y, Bruyere O, Cederholm T . Sarcopenia: revised European consensus on definition and diagnosis. Age Ageing. 2019; 48(4):601. PMC: 6593317. DOI: 10.1093/ageing/afz046. View

Cruz-Jentoft A, Baeyens J, Bauer J, Boirie Y, Cederholm T, Landi F . Sarcopenia: European consensus on definition and diagnosis: Report of the European Working Group on Sarcopenia in Older People. Age Ageing. 2010; 39(4):412-23. PMC: 2886201. DOI: 10.1093/ageing/afq034. View

Martin L, Birdsell L, MacDonald N, Reiman T, Clandinin M, McCargar L . Cancer cachexia in the age of obesity: skeletal muscle depletion is a powerful prognostic factor, independent of body mass index. J Clin Oncol. 2013; 31(12):1539-47. DOI: 10.1200/JCO.2012.45.2722. View

Begini P, Gigante E, Antonelli G, Carbonetti F, Iannicelli E, Anania G . Sarcopenia predicts reduced survival in patients with hepatocellular carcinoma at first diagnosis. Ann Hepatol. 2017; 16(1):107-114. DOI: 10.5604/16652681.1226821. View

10.

Salinas-Miranda E, Deniffel D, Dong X, Healy G, Khalvati F, OKane G . Prognostic value of early changes in CT-measured body composition in patients receiving chemotherapy for unresectable pancreatic cancer. Eur Radiol. 2021; 31(11):8662-8670. DOI: 10.1007/s00330-021-07899-6. View

11.

Prado C, Baracos V, McCargar L, Reiman T, Mourtzakis M, Tonkin K . Sarcopenia as a determinant of chemotherapy toxicity and time to tumor progression in metastatic breast cancer patients receiving capecitabine treatment. Clin Cancer Res. 2009; 15(8):2920-6. DOI: 10.1158/1078-0432.CCR-08-2242. View

12.

Galvao D, Taaffe D, Spry N, Joseph D, Newton R . Combined resistance and aerobic exercise program reverses muscle loss in men undergoing androgen suppression therapy for prostate cancer without bone metastases: a randomized controlled trial. J Clin Oncol. 2009; 28(2):340-7. DOI: 10.1200/JCO.2009.23.2488. View

13.

Antoun S, Baracos V, Birdsell L, Escudier B, Sawyer M . Low body mass index and sarcopenia associated with dose-limiting toxicity of sorafenib in patients with renal cell carcinoma. Ann Oncol. 2010; 21(8):1594-1598. DOI: 10.1093/annonc/mdp605. View

14.

Valero 3rd V, Amini N, Spolverato G, Weiss M, Hirose K, Dagher N . Sarcopenia adversely impacts postoperative complications following resection or transplantation in patients with primary liver tumors. J Gastrointest Surg. 2014; 19(2):272-81. PMC: 4332815. DOI: 10.1007/s11605-014-2680-4. View

15.

Denys A, Pracht M, Duran R, Guiu B, Adib S, Boubaker A . How to Prepare a Patient for Transarterial Radioembolization? A Practical Guide. Cardiovasc Intervent Radiol. 2015; 38(4):794-805. DOI: 10.1007/s00270-015-1071-x. View

16.

Kennedy A, Nag S, Salem R, Murthy R, McEwan A, Nutting C . Recommendations for radioembolization of hepatic malignancies using yttrium-90 microsphere brachytherapy: a consensus panel report from the radioembolization brachytherapy oncology consortium. Int J Radiat Oncol Biol Phys. 2007; 68(1):13-23. DOI: 10.1016/j.ijrobp.2006.11.060. View

17.

Lau W, Kennedy A, Kim Y, Lai H, Lee R, Leung T . Patient selection and activity planning guide for selective internal radiotherapy with yttrium-90 resin microspheres. Int J Radiat Oncol Biol Phys. 2010; 82(1):401-7. DOI: 10.1016/j.ijrobp.2010.08.015. View

18.

Prado C, Lieffers J, McCargar L, Reiman T, Sawyer M, Martin L . Prevalence and clinical implications of sarcopenic obesity in patients with solid tumours of the respiratory and gastrointestinal tracts: a population-based study. Lancet Oncol. 2008; 9(7):629-35. DOI: 10.1016/S1470-2045(08)70153-0. View